Showing results (1361-1370 of 1,373) with videos related to
Sort By:
Pageof 138
Blood|November 19, 2017
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myelomaThierry Facon, Meletios A Dimopoulos, Angela Dispenzieri, et al.Journal of Clinical Immunology|May 12, 2023
JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach StudyMarie-Louise Frémond, Marie Hully, Benjamin Fournier, et al.The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.Future Oncology (London, England)|September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.Archivos De Cardiologia De Mexico|June 28, 2012
[Conflict of interest policies and disclosure requirements among European Society of Cardiology national cardiovascular journals]Fernando Alfonso, Adam Timmis, Fausto J Pinto, et al.Blood|January 22, 2025
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS TrialAurore Perrot, Cyrille Touzeau, Jerome Lambert, et al.Haematologica|April 20, 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 studyAlexis Talbot, Arthur Bobin, Léa Tabone, et al.The Lancet. Oncology|June 18, 2024
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.The Lancet. Oncology|September 16, 2021
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.Blood|May 5, 2022
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 studyMurielle Roussel, Valérie Lauwers-Cances, Margaret Macro, et al.Pageof 138